Browse Studies — Arctuva

Phase 3

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Crinetics Pharmaceuticals Inc.NCT07144163

Phase 2

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participan…

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Crinetics Pharmaceuticals Inc.NCT07159841

Phase 2

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Crinetics Pharmaceuticals Inc.NCT06712823